Episodic Cluster Headache
10
0
0
4
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
7 treatments under study, led by Zucapsaicin
Research Leaders
11 sponsors active, led by Winston Laboratories
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
20.0%
2 terminated out of 10 trials
66.7%
-19.9% vs benchmark
80%
8 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (10)
Pulsed Radiofrequency Combined With Platelet-Rich Plasma Applied to the Sphenopalatine Ganglion in Treating Episodic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
Civamide Nasal Solution for Cluster Headache
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
R-Verapamil for the Prophylaxis of Episodic Cluster Headache
A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache
Intranasal Civamide for Episodic Cluster Headache
Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache
Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache
Research Network
Common Treatments
- Zucapsaicin3
- Galcanezumab2
- Fremanezumab1
- Placebo Matching Active Ingredient Encapsulated Tablets1
- Rverapamil 75 Mg Tablet1
Active Sponsors
- Winston Laboratories3
- Eli Lilly and Company2
- Center Laboratories, Inc.1
- Huadong Hospital1
- People's Hospital of Zhengzhou University1
Top Investigators
Winston Laboratories
Winston Laboratories
Winston Laboratories
Diamond Headache Clinic
Related Conditions
- Chronic Cluster Headache2
- Pain Management1
- Cluster Headache1